<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629391</url>
  </required_header>
  <id_info>
    <org_study_id>2019-02471</org_study_id>
    <nct_id>NCT04629391</nct_id>
  </id_info>
  <brief_title>Anatomic TSA vs RTSA for Glenohumeral Arthritis</brief_title>
  <official_title>Anatomic Versus Reverse Shoulder Arthroplasty for Primary Glenohumeral Osteoarthritis. A Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>La Tour Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>La Tour Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no published prospective studies that compared 2-year functional outcomes of RTSA&#xD;
      and anatomic TSA for the treatment of primary glenohumeral osteoarthritis with intact rotator&#xD;
      cuffs and no excessive glenoid retroversion. The primary goal of our prospective randomized&#xD;
      study is to determine whether RTSA have at least as good results as anatomic TSA&#xD;
      (non-inferiority), in patients with glenohumeral osteoarthritis, without rotator cuff tears&#xD;
      nor significant glenoid retroversion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total anatomic shoulder arthroplasty (TSA) is an effective treatment of severe glenohumeral&#xD;
      osteoarthritis, with significant improvement in shoulder pain and function. Concerns about&#xD;
      glenoid loosening, associated with difficult revision procedures and disappointing outcomes,&#xD;
      have however been raised.&#xD;
&#xD;
      Reverse total shoulder arthroplasty (RTSA) was designed with a medialized center of rotation&#xD;
      to treat cuff tear arthropathy. Favorable early reports led to the expansion of primary&#xD;
      indications of RTSA to proximal humeral fractures as well as osteoarthritis with poor glenoid&#xD;
      bone stock. Recent reports revealed excellent clinical results of RTSA for primary&#xD;
      glenohumeral arthropathy with intact rotator cuff and a low rate of complications.&#xD;
&#xD;
      Retrospective studies comparing functional results - of anatomic TSA for treating&#xD;
      glenohumeral osteoarthritis with RTSA for rotator cuff arthropathy - found equivalent or&#xD;
      greater improvements in American Shoulder and Elbow Surgeons score (ASES) at &gt;2-year&#xD;
      follow-up. In a study comparing anatomic TSA to RTSA for the treatment of glenohumeral&#xD;
      osteoarthritis with intact rotator cuffs, Steen et al. reported equivalent functional results&#xD;
      at &gt;2-year follow-up. The retrospective matched cohort study could, however, not eliminate&#xD;
      biases, such that RTSA patients had higher preoperative glenoid retroversion than anatomic&#xD;
      TSA patients. The authors therefore hypothesize that, in patients treated for glenohumeral&#xD;
      osteoarthritis without excessive glenoid retroversion, RTSA will render better functional&#xD;
      outcomes than anatomic TSA, at 2 postoperative years. Many other studies confirmed in 2019&#xD;
      Steen's hypothesis. Moreover, several studies revealed good long-term survivorship after&#xD;
      RTSA.&#xD;
&#xD;
      There are no published prospective studies that compared 2-year functional outcomes of RTSA&#xD;
      and anatomic TSA for the treatment of primary glenohumeral osteoarthritis with intact rotator&#xD;
      cuffs and no excessive glenoid retroversion. The primary goal of our prospective randomized&#xD;
      study is to determine whether RTSA have at least as good results as anatomic TSA&#xD;
      (non-inferiority), in patients with glenohumeral osteoarthritis, without rotator cuff tears&#xD;
      nor significant glenoid retroversion.The secondary goals are 1) to evaluate whether RTSA&#xD;
      eventually grants superior postoperative clinical and radiographic outcomes than anatomic TSA&#xD;
      (superiority), 2) to determine whether RTSA is associated with fewer postoperative&#xD;
      complications than anatomic TSA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>While the patients and care providers will be aware of the type of prosthesis, the physicians who assessed the outcomes and analyzed the data will be blinded to this information.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in American Shoulder and Elbow Surgeons score (ASES)</measure>
    <time_frame>Between baseline and 2 postoperative years</time_frame>
    <description>General clinical score (0-100, with 100 being the best score possible)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Subjective Shoulder Value (SSV)</measure>
    <time_frame>Between baseline and 2 postoperative years</time_frame>
    <description>General clinical score (0-100, with 100 being the best score possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Range of motion in degrees</measure>
    <time_frame>Between baseline and 2 postoperative years</time_frame>
    <description>(anterior forward flexion, external rotation at the side, internal rotation to nearest spinal level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rates</measure>
    <time_frame>2 postoperative years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain on visual analogic scale (pVAS)</measure>
    <time_frame>Between baseline and 2 postoperative years</time_frame>
    <description>General clinical score (0-10, with 10 the worst score possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Constant score</measure>
    <time_frame>Between baseline and 2 postoperative years</time_frame>
    <description>General clinical score (0-100, with 100 being the best score possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form -12 (SF-12)</measure>
    <time_frame>Between baseline and 2 postoperative years</time_frame>
    <description>General clinical score (0-100, with 100 being the best score possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic outcomes</measure>
    <time_frame>2 postoperative years</time_frame>
    <description>Rates of aseptic loosening, implant migration, implant tilt, scapular notching, glenoid bone loss as defined previously by the investigator</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">296</enrollment>
  <condition>Arthritis Shoulder</condition>
  <arm_group>
    <arm_group_label>Anatomic TSA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will receive through a deltopectoral approach an anatomic total shoulder arthroplasty (TSA) for a primary glenohumeral arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RTSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will receive through a deltopectoral approach a reverse total shoulder arthroplasty RTSA for a primary glenohumeral arthritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total shoulder arthroplasty</intervention_name>
    <description>A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.</description>
    <arm_group_label>Anatomic TSA</arm_group_label>
    <arm_group_label>RTSA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary glenohumeral arthritis,&#xD;
&#xD;
          -  Intact rotator cuff,&#xD;
&#xD;
          -  No important glenoid bone loss (cf exclusion criteria),&#xD;
&#xD;
          -  Patients between 65 and 85 years old&#xD;
&#xD;
          -  Informed Consent as documented by signature (Appendix Informed Consent Form).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  B2 glenoid with &gt; 80% posterior humeral head subluxation or greater 25 degrees&#xD;
             neoglenoid retroversion,&#xD;
&#xD;
          -  B3 and C type glenoids,&#xD;
&#xD;
          -  Full thickness rotator cuff tear,&#xD;
&#xD;
          -  Acute or malunited proximal humeral fracture,&#xD;
&#xD;
          -  Chronic locked dislocation&#xD;
&#xD;
          -  Rheumatoid arthritis,&#xD;
&#xD;
          -  Revision surgery or surgical antecedents,&#xD;
&#xD;
          -  Tumors,&#xD;
&#xD;
          -  Axillary nerve damage,&#xD;
&#xD;
          -  Non-functioning deltoid muscle,&#xD;
&#xD;
          -  Glenoid vault deficiency precluding baseplate fixation,&#xD;
&#xD;
          -  Infection and neuropathic joints,&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse,&#xD;
&#xD;
          -  Patients incapable of judgement or under tutelage,&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, contraindication for CT scan etc. of the&#xD;
             participant,&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Lädermann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Tour Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Lädermann, MD</last_name>
    <phone>+41 22 719 75 55</phone>
    <email>alexandre.laedermann@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>La Tour Hospital</name>
      <address>
        <city>Meyrin</city>
        <zip>1217</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Lädermann, MD</last_name>
      <phone>+41 22 719 75 55</phone>
      <email>alexandre.laedermann@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>La Tour Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Alexandre Lädermann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>shoulder</keyword>
  <keyword>primary osteoarthritis</keyword>
  <keyword>Range of motion</keyword>
  <keyword>clinical outcomes</keyword>
  <keyword>radiographic outcomes</keyword>
  <keyword>anatomic prosthesis</keyword>
  <keyword>reverse prosthesis</keyword>
  <keyword>Arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

